Catalog No.
DHF92406
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2a
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q02223 & P07766
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, BCMA, PF-06863135, PF-3135, CAS: 2408850-14-4
Clone ID
Elranatamab
Note
For research use only. Not suitable for clinical or therapeutic use.
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment., PMID:38004493
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma., PMID:38078866
Antibodies to watch in 2024., PMID:38178784
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms., PMID:38194680
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma., PMID:38347747
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma., PMID:38415370
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3., PMID:38420657
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study., PMID:38432433
A pivotal decade for bispecific antibodies?, PMID:38465614
Clonal CD8+ T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma., PMID:38546659
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan., PMID:38687406
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma., PMID:38717927
Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3., PMID:38794892
Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis., PMID:38817306
Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy., PMID:38940040
A tertiary care centre experience with Elranatamab: A report of three cases., PMID:38974232
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study., PMID:39055646
[Elranatamab monotherapy in multiple myeloma after at least three prior treatments]., PMID:39227195
B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice., PMID:39373355
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma., PMID:39415515
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System., PMID:39458907
Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection., PMID:39617677
Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives., PMID:39676006
Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report., PMID:39676854
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM., PMID:39695076
Practical insights into bispecific antibody therapy in multiple myeloma., PMID:39729045
Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With Multiple Myeloma Treated With Elranatamab., PMID:39744308
Update on B-cell maturation antigen-directed therapies in AL amyloidosis., PMID:39748220
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era., PMID:39809660
Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab., PMID:39865264
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead., PMID:39880754
A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients., PMID:39955765
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database., PMID:39982395
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma., PMID:40000533
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review., PMID:40052837
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System., PMID:40095047
Elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison., PMID:40190254
Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain., PMID:40193043
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma., PMID:40225701
Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system., PMID:40302414
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract., PMID:40345961
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial., PMID:40383818
Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results., PMID:40384938
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma., PMID:40491859
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States., PMID:40495704
For research use only. Not for human or drug use.
